STING agonist-1 is primarily utilized in immunotherapy and cancer research due to its ability to activate the STING (stimulator of interferon genes) pathway. This activation triggers the production of type I interferons and other cytokines, which enhance the immune system's ability to target and destroy cancer cells. It is being explored as a potential therapeutic agent in various cancer treatments, particularly in combination with other immunotherapies like checkpoint inhibitors. Additionally, it is studied for its role in improving vaccine efficacy by boosting immune responses. Researchers are also investigating its potential in treating viral infections, as the STING pathway plays a critical role in antiviral defense mechanisms.